We have read with great interest the comments of Leone et al. 1 indicating that they have analyzed a series of 23 cases of lung sarcomatoid carcinomas (SC) and found 2 cases harboring an EGFR mutation. At the time of this writing, 78 cases 1- 7 and 58 cases 1,2,6 of SC have been screened for EGFR an
Identification of EGFR mutations in lung sarcomatoid carcinoma
β Scribed by Alvaro Leone; Paolo Graziano; Rita Gasbarra; Gregorino Paone; Giuseppe Cardillo; Andrea Mancuso; Filippo De Marinis; Serena Ricciardi; Luigi Portalone; Roberto Pisa
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- French
- Weight
- 237 KB
- Volume
- 128
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Sarcomatoid carcinomas (SC) of the lung are uncommon malignant tumors composed of carcinomatous and sarcomatous cell components and characterized by a more aggressive outcome than other histological subtypes of nonsmall cell lung cancer (NSCLC). Although epidermal growth factor receptor
## Abstract Lung adenocarcinomas often metastasize to the brain, and the prognosis of patients with brain metastases is still very poor. The __epidermal growth factor receptor__ (__EGFR__) gene is mutated in a considerable fraction of primary lung adenocarcinomas, in particular those with drastic r
## Abstract Mutations of the epidermal growth factor receptor gene (__EGFR__) have been reported to be present in a considerable fraction of lung adenocarcinomas showing dramatic response to EGFR tyrosine kinase inhibitors. To clarify pathogenic significance of the mutations for the development of